Inactive Instrument

Proteostasis Therapeutics, Inc.

Equities

PTI

US74373B1098

Proteostasis Therapeutics, Inc. Appoints David Arkowitz to Board of Directors

March 07, 2019 at 05:30 pm IST

Proteostasis Therapeutics, Inc. announced that David Arkowitz has been appointed to the company's Board of Directors. Mr. Arkowitz is the Chief Financial Officer and Treasurer of Flexion Therapeutics.

Latest news about Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc.(NasdaqGM:PTI) dropped from NASDAQ Composite Index	23/20/23	CI
Yumanity Therapeutics Inc. completed the acquisition of Proteostasis Therapeutics, Inc. in a reverse merger transaction.	22/20/22	CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	17/20/17	CI
Proteostasis Therapeutics, Inc. Announces Resignation of Sheila Wilson as Chief Operating Officer	25/20/25	CI
Proteostasis Therapeutics : Biotech Startup Yumanity Sets Reverse Merger With Proteostasis	24/20/24	DJ
Transcript : Proteostasis Therapeutics, Inc., Yumanity Therapeutics Inc. - M&A Call	24/20/24
Yumanity Therapeutics Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Proteostasis Therapeutics, Inc. for approximately $150 million in a reverse merger transaction.	24/20/24	CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	07/20/07	CI
Proteostasis Therapeutics, Inc.(NasdaqGM:PTI) added to Russell Microcap Growth Index	29/20/29	CI
Wall Street closes higher as recovery signs soothe protest, pandemic worries	02/20/02	RE
Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19	01/20/01	CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	16/20/16	CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	11/20/11	CI
Proteostasis Therapeutics, Inc. Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic Fibrosis	25/20/25	CI
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis	24/20/24	CI
Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients	22/20/22	CI
Proteostasis Therapeutics Provides Regulatory Update Following Scientific Advice Meeting with MHRA	13/20/13	CI
Proteostasis Therapeutics, Inc.(NasdaqGM:PTI) dropped from NASDAQ Biotechnology Index	23/19/23	CI
Transcript : Proteostasis Therapeutics, Inc. - Special Call	17/19/17
Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients	17/19/17	CI
Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators	11/19/11	CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	08/19/08	CI
Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis	06/19/06	CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	08/19/08	CI
Proteostasis Therapeutics, Inc. Initiates Dosing in Global Phase 2 Study in Cystic Fibrosis	25/19/25	CI

Chart Proteostasis Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company's pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

Sector

More about the company